Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
General Pharmacometrics
Home
General Pharmacometrics
General Pharmacometrics
Type here to filter the list
(M-001) Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis
Favorite
(M-009) Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
Favorite
(M-011) A Survey of Model Informed Approaches in Neuroscience Drug Development
Favorite
(M-015) Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain
Favorite
(M-017) A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
Favorite
(M-018) Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis
Favorite
(M-019) Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes
Favorite
(M-026) Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
Favorite
(M-027) Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
Favorite
(M-031) Development and application of a mechanistic model for Alzheimer’s Disease
Favorite
(M-034) Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
Favorite
(M-035) PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody
Favorite
(M-037) K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Favorite
(M-038) K-PD Modeling of Plozasiran - Mixed Hyperlipidemia
Favorite
(M-041) Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study
Favorite
(M-042) Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection
Favorite
(M-043) Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis
Favorite
(M-045) Visual predictive check of longitudinal models and dropout
Favorite
(M-047) Population Pharmacokinetics of Nivolumab in Patients with Newly Diagnosed or Relapsed/Refractory Classical Hodgkin Lymphoma
Favorite
(M-049) Disease Progression Modeling of Stargardt’s disease
Favorite
(M-050) Exposure-Response Analysis of Cenobamate
Favorite
(M-051) The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM
Favorite
(M-052) Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin
Favorite
(M-053) PKPD modeling and simulation of an inhaled antibiotic targeting Gram-negative bacteria, using a bacteriophage-derived endolysin.
Favorite
(M-057) A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model
Favorite
(M-058) Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection of S-001, a Novel mRNA-based Therapy for Pancreatic Cancer
Favorite
(M-060) Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia
Favorite
(M-062) Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
Favorite
(M-063) Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction
Favorite
(M-064) A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users
Favorite
(M-067) Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies
Favorite
(M-070) Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose
Favorite
(M-074) Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Favorite
(M-075) Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Favorite
(M-077) Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis
Favorite
(M-079) Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
Favorite
(M-082) Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Favorite
(M-084) Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged <12 Months
Favorite
(M-086) Population Pharmacokinetic (Pop PK) Modeling of Nirmatrelvir/Ritonavir in Severe Renal Impaired Participants with COVID-19 either on or not on Hemodialysis
Favorite
(M-088) Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics
Favorite
(M-095) Population Pharmacokinetic Modeling Informed the Dose of GDC-8264 for a Phase 1b Study in Participants with Acute Graft-Versus-Host Disease
Favorite
(M-096) Population pharmacokinetics analysis of DA-8010, a novel anti-muscarinic agent
Favorite
(M-098) Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis
Favorite
(M-099) Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
Favorite
(M-102) Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients
Favorite
(M-106) A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
Favorite
(M-108) How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches
Favorite
(M-111) Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context
Favorite
(M-112) Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods
Favorite
(M-115) Population Pharmacokinetic and Exposure-Response Analyses of Tasurgratinib in Subjects with Unresectable Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Gene Fusion
Favorite
(M-116) Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data
Favorite
(M-117) Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment
Favorite
(M-118) Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
Favorite
(M-119) Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Favorite
(M-121) Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug
Favorite
(M-123) Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection
Favorite
(M-128) Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease
Favorite
(M-132) Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen
Favorite
(M-133) Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Favorite
(M-135) A Bayesian disease progression model for Major Depressive Disorder
Favorite
(M-136) A time-to-event model for Bronchopulmonary dysplasia based on real-world data
Favorite
(M-137) A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Favorite
(M-138) Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Favorite
(M-139) Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma
Favorite
(M-140) Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
Favorite
(M-141) Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration
Favorite
(T-005) A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
Favorite
(T-007) Population Pharmacokinetics of Enoxaparin in Neonates and Infants
Favorite
(T-011) A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Favorite
(T-012) popPK & ER analysis of amivantamab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure
Favorite
(T-014) Longitudinal Population Pharmacokinetic/Pharmacodynamic Modeling of Continuous Efficacy Endpoint and Biomarker for a Novel Compound
Favorite
(T-020) Zolpidemsim: A Web-Application for Simulating Pharmacokinetics of Zolpidem
Favorite
(T-022) Comparing the Efficacy of Various Insulin Types: A Pharmacokinetic and Pharmacodynamic Modeling Study in Healthy Volunteers
Favorite
(T-023) Cost-effectiveness of paliperidone palmitate long-acting injectables for the treatment of schizophrenic patients: a joint pharmacometric/pharmacoeconomic approach
Favorite
(T-026) A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Favorite
(T-028) Pooled population PK of alpelisib in patients with PIK3CA-related overgrowth spectrum and breast cancer
Favorite
(T-036) A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Favorite
(T-037) Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC
Favorite
(T-040) How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition Using Open-Source Julia Tools
Favorite
(T-041) Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa
Favorite
(T-046) A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
Favorite
(T-048) App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
Favorite
(T-051) Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases
Favorite
(T-052) Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study
Favorite
(T-053) Modeling and inter-species scaling of plasma DHO as a biomarker to inform first-in-human dose selection for a novel DHODH inhibitor
Favorite
(T-054) The effect of CYP2B6 genotype on the clearance and autoinduction of efavirenz in healthy subjects and the subsequent impact on efavirenz exposure.
Favorite
(T-055) Population PK model on preclinical data for optimization of further clinical trial designs in oncology
Favorite
(T-056) A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
Favorite
(T-057) Hybrid Population PK-Machine Learning Model Approach to Predict Infliximab Concentrations in Pediatric Patients with Crohn's Disease
Favorite
(T-058) Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients
Favorite
(T-059) Population Pharmacokinetic Approach to Evaluate Current Recommended Dose of Tacrolimus on Korean Pediatric Liver Transplant Patients
Favorite
(T-064) Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors
Favorite
(T-069) Assessment of Disease Similarity among Different Racial and/or Ethnic Groups in Oncology: ABC Framework
Favorite
(T-070) A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
Favorite
(T-072) Exposure–Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Favorite
(T-076) Population Pharmacokinetic-Pharmacodynamic Modeling for Triapine to Optimize Dosing Regimen
Favorite
(T-080) A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
Favorite
(T-081) Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
Favorite
(T-087) Population pharmacokinetics of cefepime in critically ill children and young adults
Favorite
(T-089) Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
Favorite
(T-091) Fast Stepwise Selection Methods for Efficient Covariate Model Development in Population Data Analysis
Favorite
(T-093) Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment
Favorite
(T-094) Cellular and Humoral Semi-mechanistic Immune Response Models of a Vaccine Candidate for Respiratory Syncytial Virus Infection
Favorite
(T-098) Population pharmacokinetic modeling of Binimetinib in Healthy Volunteers and Participants with BRAF V600-mutant or NRAS-mutant Solid Tumors
Favorite
(T-099) Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Favorite
(T-103) A model-based simulation workflow enables automated and accurate generation of clinical pharmacology summary statistics, a workflow and case-study.
Favorite
(T-109) Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders
Favorite
(T-110) Simulation of Trial Predictions with Model Uncertainty using NMsim
Favorite
(T-116) A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
Favorite
(T-118) Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
Favorite
(T-119) Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients
Favorite
(T-120) Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
Favorite
(T-121) Joint bi-directional PK-ADA population modelling in immuno-oncology
Favorite
(T-123) Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections
Favorite
(T-124) Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
Favorite
(T-125) Beyond the Michaelis-Menten: Evaluation of Novel IVIVE Approach for Predicting In Vivo Intrinsic Clearance from Hepatocyte Assays
Favorite
(T-126) Quantification of uncertainty in human dose predictions
Favorite
(T-127) Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton’s tyrosine kinase inhibitor case study
Favorite
(T-128) Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
Favorite
(T-132) Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials
Favorite
(T-133) Placebo Response Model for Alopecia Areata: A Model-based Meta-analysis of Randomized Controlled Trials
Favorite
(T-139) Population Pharmacokinetics and Exposure-response Analyses of Amivantamab Administered in Combination with Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Favorite
(T-140) Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy
Favorite
(T-141) Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
Favorite
(T-142) PK-PD modeling of doxycycline, azithromycin, and their combination in treating severe scrub typhus using a general pharmacodynamic interaction (GPDI) model.
Favorite
(W-008) The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships
Favorite
(W-011) Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections
Favorite
(W-013) Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration
Favorite
(W-019) Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
Favorite
(W-020) In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
Favorite
(W-022) Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
Favorite
(W-023) Optimized Noncompartmental Half-Life Estimation with Tobit Regression
Favorite
(W-025) Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers
Favorite
(W-026) Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers
Favorite
(W-027) Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants
Favorite
(W-030) Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies
Favorite
(W-036) Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
Favorite
(W-042) Population Pharmacokinetic Modeling of Hydroxyurea in Plasma and Breast Milk in Lactating Women
Favorite
(W-043) Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy
Favorite
(W-044) Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Favorite
(W-045) Clinical Trial Simulation to Assess Sample Size and Power For Detecting Differences in Pharmacokinetic Exposure Metrics
Favorite
(W-046) Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Favorite
(W-047) Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design
Favorite
(W-048) Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366
Favorite
(W-049) Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Favorite
(W-050) Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction
Favorite
(W-051) Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations
Favorite
(W-054) Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer
Favorite
(W-055) Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses
Favorite
(W-056) Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
Favorite
(W-062) SEMI-PHYSIOLOGIC POPULATION PHARMACOKINETIC MODEL TO EVALUATE THE EFFECT OF HEPATIC-UPTAKE TRANSPORTER GENE SLC22A1 POLYMORPHISM ON PHARMACOKINETICS OF PROGUANIL AND ITS METABOLITE, CYCLOGUANIL
Favorite
(W-064) Comparative evaluation of different vancomycin population pharmacokinetic models to predict Bayesian-estimated vancomycin AUC in Korean patients
Favorite
(W-065) Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation
Favorite
(W-067) Gauss-Hermite cohort population estimation of dexamethasone pharmacokinetic parameters in pregnant women using blood samples collected at birth
Favorite
(W-068) Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation
Favorite
(W-070) Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors
Favorite
(W-074) Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Favorite
(W-075) Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics
Favorite
(W-078) Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy
Favorite
(W-079) Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy
Favorite
(W-080) Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data
Favorite
(W-082) Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer
Favorite
(W-083) Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Favorite
(W-089) Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach
Favorite
(W-091) Characterization of the Effect of Biofilm Formation on the Antimicrobial Activity of Tigecycline against M. abscessus using a Hollow Fiber Infection Model and Pharmacokinetic/Pharmacodynamic Modeling
Favorite
(W-093) Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation
Favorite
(W-094) Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
Favorite
(W-099) Constructing a virtual control arm and evaluating operating characteristics using TGI metrics to support go/no-go decisions for single-arm Phase Ib/II combination studies
Favorite
(W-100) Pharmacometrics-Based Evaluation of Fixed versus Weight-Based Dosing Strategies for Approved Antibody Drug Conjugates (ADC)
Favorite
(W-103) Prediction of the Biological Effect of PEG-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach
Favorite
(W-105) Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models
Favorite
(W-106) Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach
Favorite
(W-108) Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
Favorite
(W-110) PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis
Favorite
(W-112) Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Favorite
(W-113) Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer
Favorite
(W-118) Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations
Favorite
(W-121) Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function
Favorite
(W-122) Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
Favorite
(W-123) Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients
Favorite
(W-125) Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel
Favorite
(W-126) Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents
Favorite
(W-127) Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.
Favorite
(W-128) Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)
Favorite
(W-132) Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
Favorite
(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Favorite
(W-140) Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
Favorite
(W-141) Disease progression modeling of myositis from real-world data
Favorite
(W-142) Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC
Favorite
